WntResearch AB — Investor Relations & Filings

WntResearch AB was a pharmaceutical development company focused on creating a new class of anti-metastatic cancer drugs. Its primary drug candidate, Foxy-5, is a peptide that mimics the Wnt-5a protein. The therapeutic strategy is based on research indicating that reduced levels of Wnt-5a correlate with an increased risk of tumor cell spread. Foxy-5 was developed to inhibit the ability of cancer cells to metastasize, with the goal of improving survival rates for patients with various forms of cancer. In early 2025, the company completed a reverse acquisition of OPSY AB and was subsequently renamed Opsy Holding AB.